Cephaloridine

Summary

Cephaloridine (CHEMBL316157) is an approved small-molecule antibacterial drug (ATC J01DB02); indicated across 1 condition including bacterial infectious disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J01DB02
• Indications: 1 condition
• Chemistry: 415.5 Da · C19H17N3O4S2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL316157
Name	Cephaloridine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	5773
ChEBI	CHEBI:3537
ATC	J01DB02
Molecular formula	C19H17N3O4S2
Molecular weight	415.5
InChIKey	CZTQZXZIADLWOZ-CRAIPNDOSA-N

SMILES: C1C(=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)CC3=CC=CS3)C(=O)[O-])C[N+]4=CC=CC=C4

IUPAC name: (6R,7R)-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate

ChEBI definition: A cephalosporin compound having pyridinium-1-ylmethyl and 2-thienylacetamido side-groups. A first-generation semisynthetic derivative of cephalosporin C.

Pharmacological roles (ChEBI): antibacterial drug.

Also known as: Cefaloridina, Cefaloridine, Cephaloridine, cephaloridine, cefaloridine, CEPHALORIDINE, CEFALORIDINE, SID144204921

Patent coverage: 21,218 distinct patent families (45,474 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 6 (assay-derived). Sample: Solute carrier family 22 member 6, Organic anion transporter 3, Solute carrier family 22 member 11, Prostaglandin G/H synthase 1, Solute carrier family 15 member 2, Nuclear receptor subfamily 1 group I member 2.

Bioactivity

ChEMBL activities: 5 potent at pChembl ≥ 5 of 6 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
SLC22A6	6.13	Ki	740	nM	CHEMBL_ACT_11002303
SLC22A8	5.61	Ki	2460	nM	CHEMBL_ACT_11002752
NR1I2	5.5	EC50	3200	nM	CHEMBL_ACT_15465470
SLC22A11	5.44	Ki	3630	nM	CHEMBL_ACT_11002863
Q63424	5.07	Ki	8500	nM	CHEMBL_ACT_11003288

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).